1,987 results on '"Pol, Stanislas"'
Search Results
2. Impaired health-related quality of life in the HCV cure era: who is concerned? (ANRS CO22 HEPATHER French cohort)
3. Impact of HCV cure on subsequent hospitalizations in people with mental disorders: Results from the French claims database
4. Treatment with bulevirtide in HIV-infected patients with chronic hepatitis D: ANRS HD EP01 BuleDelta and compassionate cohort
5. Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes
6. Effect of Peg-IFN on the viral kinetics of patients with HDV infection treated with bulevirtide
7. Direct-Acting Antivirals and the Risk of Arrhythmias and Conduction Disorders in Patients with Chronic Hepatitis C: A French Nationwide Cohort Study
8. Unknown Circovirus in Immunosuppressed Patient with Hepatitis, France, 2022
9. Alcohol Rehabilitation Within 3 Months After Alcohol Hepatitis and Survival - A National Analysis
10. Burden of grade 3 or 4 liver injury associated with immune checkpoint inhibitors
11. Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area: What's new 12 months later?
12. Diversity of the nucleic acid forms of circulating HBV in chronically infected patients and its impact on viral cycle
13. Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis
14. Low alcohol consumption influences outcomes in individuals with alcohol-related compensated cirrhosis in a French multicenter cohort
15. Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D
16. WED-245 Should specific cutoffs be used for diagnosing fibrotic MASH in patients with type 2 diabetes using FAST, MAST, MEFIB and FNI?
17. GS-002 48-week off-therapy efficacy and safety of bulevirtide in combination with pegylated interferon alfa-2a in patients with chronic hepatitis delta: final results from the phase 2b, open-label, randomised, multicentre study MYR204
18. FRI-361 Burden of liver disease progression in patients with chronic HDV infection: a population-based study for France
19. FRI-371 Undetectable HDV RNA at 24 weeks of treatment with combination therapy is an important predictor of maintained response off-therapy
20. WED-410 Sustained virological response after treatment with Bulevirtide in HDV patients. Data from the french multicenter real-life cohort
21. WED-391 Long-term virological and clinical outcomes of patients with HDV-related compensated cirrhosis treated with bulevirtide monotherapy for up to 120 weeks: a retrospective multicenter european study (save-d)
22. OS-120 Bulevirtide monotherapy prevents liver decompensation and reduces mortality in patients with HDV-related cirrhosis: a case control study with propensity score weighted analysis
23. SAT-343 Impact of hepatitis C virus direct acting antivirals on hepatocellular carcinoma evolution
24. OS-077 Added value of a combination of positron emission tomography with 18F-FDG and 18 F-Fluorocholine for staging optimization and treatment modification in patients with hepatocellular carcinoma: the prospective multicentric PET HCC01 study
25. OS-060 Hepatocellular carcinoma development despite histological regression of liver fibrosis following HCV cure (ANRS CirVir, Hepather, LICAVIR)
26. Executive Summary of the KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease
27. Severe liver fibrosis in the HCV cure era: Major effects of social vulnerability, diabetes, and unhealthy behaviors
28. Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals
29. Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis
30. Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort
31. External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B
32. Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis
33. Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes
34. Impact of Hepatitis C Virus Direct Acting Antivirals on Hepatocellular Carcinoma Evolution
35. External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV
36. Impact of cirrhosis aetiology on incidence and prognosis of hepatocellular carcinoma diagnosed during surveillance
37. Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment
38. Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area
39. Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts
40. The clinical and financial burden of nonhepatocellular carcinoma focal lesions detected during the surveillance of patients with cirrhosis.
41. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials
42. Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2022 Clinical Practice Guideline
43. Hepatitis C virus treatment in the real world: optimising treatment and access to therapies
44. Épidémiologie de la stéato-hépatite non alcoolique. Étendue du problème et son impact sur la santé publique
45. L’index FIB-4 pour faire le diagnostic de fibrose hépatique avancée au cours de la stéatose hépatique
46. Can we differentiate HIV-associated obliterative portopathy from liver cirrhosis using MRI?
47. The remarkable history of the hepatitis C virus
48. Control of replication of hepatitis B and C virus improves patient and graft survival in kidney transplantation
49. Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy
50. Long-term Efficacy of Interferon-Free Antiviral Treatment Regimens in Patients With Hepatitis C Virus–Associated Cryoglobulinemia Vasculitis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.